Phase II Study of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Patients With Metastatic Breast Cancer

We conducted a phase II clinical trial to determine the clinical efficacy and safety of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. Patients were eligible if they had measurable disease, no prior chemotherapy for metastatic disease, and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2003-09, Vol.21 (17), p.3249-3254
Hauptverfasser:	RIVERA, Edgardo, VALERO, Vicente, ARUN, Banu, ROYCE, Melanie, ADININ, Rosni, HOELZER, Karen, WALTERS, Ronald, WADE, James L, PUSZTAI, Lajos, HORTOBAGYI, Gabriel N
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - pathology Chemotherapy Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Disease Progression Dose-Response Relationship, Drug Doxorubicin - administration & dosage Doxorubicin - adverse effects Female Humans Infusions, Intravenous Liposomes Male Medical sciences Middle Aged Pharmacology. Drug treatments Survival Analysis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We conducted a phase II clinical trial to determine the clinical efficacy and safety of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. Patients were eligible if they had measurable disease, no prior chemotherapy for metastatic disease, and a performance status
ISSN:	0732-183X 1527-7755
DOI:	10.1200/JCO.2003.03.111